Jules Bordet Institute
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 1939-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.bordet.be
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Phase 2
Completed
- Conditions
- Esophageal AdenocarcinomaEsophagus SCCCholangiocarcinomaUrothelial/Bladder Cancer, NosEndometrial Cancer
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 85
- Registration Number
- NCT03339843
- Locations
- 🇫🇷
IUCT Oncopole - Institut Claudius Regaud, Toulouse, France
🇫🇷Centre Oscar Lambret, Lille, France
🇧🇪Universitair Ziekenhuis, Antwerpen, Belgium
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
Phase 1
Withdrawn
- Conditions
- Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionSquamous Cell Carcinoma of the Esophagus
- Interventions
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT03307941
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Kadcyla In pAtients With bRAin Metastasis
Phase 2
Withdrawn
- Conditions
- Metastatic HER2-positive Breast Cancer With Brain Metastasis
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT03203616
Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)
Phase 2
- Conditions
- Refractory Chronic Graft Versus Host Disease (cGVHD)
- Interventions
- Device: Photopheresis Theraflex ECP™
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03083574
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium
🇧🇪Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03065621
- Locations
- 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪CHU Brugmann, Brussels, Belgium
🇧🇪CHU Saint-Luc, Brussels, Belgium
Randomized Controlled Trial Assessing the Efficacy of a Communication Skills Training Program
Not Applicable
- Conditions
- Physician Patient Relationship
- Interventions
- Behavioral: Communication skills training
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 72
- Registration Number
- NCT02836197
- Locations
- 🇧🇪
Libert Yves, Brussels, Belgium
🇧🇪Libert, Brussels, Belgium
Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management
Phase 2
Withdrawn
- Conditions
- Prostate Cancers
- Interventions
- Drug: 68Ga-(HBED-CC)-PSMA
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT02810886
Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption
Phase 3
Completed
- Conditions
- Locoregional Analgesia in Breast Surgery
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 54
- Registration Number
- NCT02655965
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
Phase 2
Withdrawn
- Conditions
- Breast Cancer
- Interventions
- Procedure: Breast cancer surgery
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT02338531
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇫🇷Institut Curie, Paris, France
🇧🇪CMSE, Namur, Belgium
BIG Molecular Screening Feasibility Study
Not Applicable
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- Procedure: biopsy
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02094742
- Locations
- 🇩🇪
Klinikum Offenbach, Offenbach am Main, Frankfurt, Germany
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇪🇸Val d'Hebron, Barcelona, Spain
© Copyright 2025. All Rights Reserved by MedPath